Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of “Hold” by Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has earned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $7.50.

CRDF has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. William Blair lowered shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 11th. TD Cowen cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Monday, June 1st. HC Wainwright upgraded Cardiff Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings raised Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 4th.

Institutional Trading of Cardiff Oncology

Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Cardiff Oncology in the second quarter valued at approximately $1,265,000. Glenview Trust Co purchased a new position in Cardiff Oncology in the 2nd quarter worth approximately $56,000. Capstone Investment Advisors LLC bought a new position in shares of Cardiff Oncology in the 2nd quarter worth $67,000. Hsbc Holdings PLC purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $37,000. Finally, Ieq Capital LLC purchased a new stake in shares of Cardiff Oncology during the 2nd quarter valued at $58,000. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

NASDAQ CRDF traded up $0.01 during trading hours on Friday, hitting $1.31. The company had a trading volume of 81,404 shares, compared to its average volume of 1,154,983. The firm has a market capitalization of $102.30 million, a price-to-earnings ratio of -2.19 and a beta of 1.46. Cardiff Oncology has a 52 week low of $0.76 and a 52 week high of $3.31. The firm has a 50 day simple moving average of $1.01 and a 200 day simple moving average of $1.40.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. On average, research analysts forecast that Cardiff Oncology will post -0.6 earnings per share for the current year.

More Cardiff Oncology News

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and issued more favorable earnings forecasts. The firm estimates a 2026 loss of $0.56 per share, better than the broader consensus loss of $0.61, and projects the loss narrowing to $0.33 per share in 2027. Quarterly loss estimates also improve from $0.13 per share in Q3 2026 to approximately $0.08–$0.09 per share during 2027, suggesting expectations for reduced cash burn over time. MarketBeat Cardiff Oncology analyst estimates
• Neutral Sentiment: Analyst sentiment is mixed. A separate report highlights conflicting views among analysts covering Cardiff Oncology, which may limit the impact of HC Wainwright’s Buy rating and keep trading volatile. Analysts conflicted on Cardiff Oncology
• Negative Sentiment: Cardiff Oncology continues to forecast sizable losses. The company is expected to lose $0.56 per share in 2026 and $0.33 per share in 2027, while its latest quarterly results missed the consensus EPS estimate. These losses create ongoing cash-burn and potential financing risks for investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cell division and cancer-cell growth.

Cardiff Oncology has primarily studied onvansertib in combination with existing treatments for patients with difficult-to-treat solid tumors, including KRAS-mutated metastatic colorectal cancer.